Prostatype Genomics AB announced its expansion in Germany, a key priority for the Company. Starting immediately, Karlheinz Dewald will represent the company and the Prostatype® prostate cancer test on the German market. Karlheinz Dewald will represent Prostatype Genomics in the role of Director of Market development on the German market. Karlheinz has many years’ experience from commercial roles in leading enterprises in fields like biotechnology, oncology and urology. Most recent, Karlheinz led the implementation of new molecular biomarker in oncological diagnostic and treatment monitoring in Germany, Switzerland and Austria.